Fondaparinux is an anticoagulant used in the prevention and treatment of thromboembolic
disease. It has recently been approved in the European Union (EU) for the treatment of
patients with isolated superficial vein thrombosis (SVT), i.e. without concomitant deep vein
thrombosis (DVT), of the lower limbs. As part of EU approval, GlaxoSmithKline (GSK) committed
to evaluate physicians' adherence to fondaparinux prescribing information regarding proper
diagnosis and dosing for the treatment of SVT.
The primary objective is to evaluate physicians' adherence to fondaparinux prescribing
information for the treatment of patients with SVT without concomitant DVT.
The study is designed as a non-interventional, retrospective chart review of patients
prescribed fondaparinux to treat their SVT. The study will be conducted in several EU
countries.
ARIXTRA® is a registered trademark of the GlaxoSmithKline group of companies.